Natco Pharma launches Chlorantraniliprole (CTPR) pesticide formulated combination products in India

"We estimate the market size of the CTPR combination products to be around ₹800 crore in India. NATCO is the 1st company, after Syngenta, to launch above mentioned CTPR combination products in India. It follows on the heels of indigenously manufactured CTPR formulation 18.5% SC launched by NATCO recently under brand name NATGEN," the release stated.

Read also: Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India

NATCO has challenged FMC for revocation of their patents for these combination products that are marketed by Syngenta, and the case is pending before the Hon'ble High Court of Delhi. 

Read also: Delhi HC nod to Natco Pharma for launch of Chlorantraniliprole and its formulations

Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.

Natco sells its FDF products in the United States, India, Europe and the rest of the world ("RoW"). In the API segment, the company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.

The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Read also: Natco Pharma secures USFDA nod for Trabectedin for Injection